<DOC>
	<DOCNO>NCT00775645</DOCNO>
	<brief_summary>RATIONALE : Acetyl-L-carnitine may prevent lessen neuropathy cause chemotherapy . It yet know whether acetyl-L-carnitine effective placebo prevent neuropathy cause chemotherapy . PURPOSE : This randomized phase III trial study acetyl-L-carnitine see well work compare placebo prevent neuropathy woman stage I , stage II , stage III breast cancer undergo chemotherapy .</brief_summary>
	<brief_title>S0715 : Acetyl-L-Carnitine Preventing Neuropathy Women With Stage I , II , IIIA Breast Cancer Undergoing Chemo</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare whether treatment acetyl-L-carnitine hydrochloride v placebo prevents symptom neuropathy measure 11-item neurotoxicity component FACT-Taxane Questionnaire 12 week study registration woman stage I , II , IIIA breast cancer undergo adjuvant taxane-based chemotherapy . Secondary - Compare functional status patient use Trial Outcome Index Functional Assessment Cancer Therapy ( FACT ) -Taxane Questionnaire . - Compare fatigue patient use Function Assessment Chronic Illness Therapy ( FACIT ) -Fatigue Symptom Module . Other - Compare proportion patient experience grade 2 3 neuropathy . - Compare serum nerve growth factor level patient . - Describe total dose taxane receive treatment delay , compliance therapy , use concurrent medication , dietary supplement ( e.g. , glutamine ) , vitamin E , complementary alternative medicine patient . - Explore relationship nerve growth factor level degree neuropathy functional status patient . - Explore relationship genetic marker responsible taxane metabolism clearance ( e.g. , CYP2C8 , CYP3A4 , CYP3A5 , GSTM1 , GSTP1 ) degree neuropathy patient . OUTLINE : This multicenter study . Patients stratify accord plan adjuvant chemotherapy regimen breast cancer ( paclitaxel weekly 12 week vs paclitaxel biweekly 4 course [ 8 week ] vs paclitaxel biweekly 6 course [ 12 week ] v docetaxel every 3 week 4 course [ 12 week ] v docetaxel every 3 week 6 course [ 18 week ] ) age ( &lt; 60 year vs ≥ 60 year ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral acetyl-L-carnitine hydrochloride 3 time daily 24 week . - Arm II : Patients receive oral placebo 3 time daily 24 week . Patients complete FACT-Taxane Trial Outcome Index FACIT-Fatigue Symptom Module questionnaires baseline , 12 , 24 , 36 week , 1 2 year . Blood sample collect baseline week 12 biomarker analysis ( nerve growth factor level ) ELISA , DNA extraction , genotyping analysis .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary invasive adenocarcinoma breast Stage IIII disease No metastatic disease Must undergone modify radical mastectomy breastsparing surgery Planning receive one follow standard taxanebased systemic chemotherapy regimens adjuvant therapy breast cancer : Paclitaxel 80 mg/m² weekly 12 week Paclitaxel 175 mg/m² every week 4 course ( 8 week ) Paclitaxel 175 mg/m² every week 6 course ( 12 week ) Docetaxel 75 mg/m² every 3 week 4 course ( 12 week ) Docetaxel 75 mg/m² every 3 week 6 course ( 18 week ) No history neuropathy Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify Zubrod performance status 02 Serum creatinine ≤ 2.5 time upper limit normal Not pregnant nursing Fertile patient must use effective contraception Able complete questionnaire English Spanish Willing submit blood sample DNA extraction , genotyping analysis , nerve growth factor study No history diabetes No history seizure disorder No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , ductal carcinoma situ , adequately treated stage I stage II malignancy patient currently complete remission PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior breast surgery Prior neoadjuvant adjuvant chemotherapy allow No prior taxane therapy No prior biologic therapy treatment breast cancer No concurrent vitamin E , glutamine , gabapentin , nortriptyline , amitriptyline , duloxetine hydrochloride Multivitamins contain vitamin E allow provide vitamin E dose &lt; 1,000 IU No concurrent antiseizure medication Concurrent hormonal therapy allow Concurrent biologic therapy allow ( e.g. , Herceptin ) Concurrent participation another therapeutic clinical trial allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>fatigue</keyword>
	<keyword>neuropathy</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>